Janssen M J, van Boven W P
Hospital Pharmacy, Midden-Brabant, Tilburg, The Netherlands.
Pharm World Sci. 1996 Oct;18(5):187-91. doi: 10.1007/BF00820731.
In haemodialysis patients the desferrioxamine (DFO) test is an accepted method for estimating the body content of aluminium. However, toxic side effects have been frequently reported with the high-dose (30 or 40 mg/kg) DFO tests. To study if a low-dose (500 mg) DFO test was also useful and free of side effects, we compared it with a high-dose DFO test in 22 patients on regular haemodialysis. During the first two hours of dialysis, 500 mg DFO in 100 ml 0.9% NaCl were administered intravenously. Before dialysis and after 48 hours aluminium concentration was determined in serum. In 14 patients the low-dose DFO test was considered positive. In 11 of those 14 patients the high-dose (30 mg/kg) DFO test was positive too. Analysis of the results showed a significant correlation (p < 0.05) between the outcome of the two DFO tests in the same patient. Compared to the high-dose DFO test, the low-dose test revealed a sensitivity of 79% and a specificity of 63%. In contrast with the high-dose DFO test might be a reliable and safe method for the estimation of the body content of aluminium in patients on regular haemodialysis.
在血液透析患者中，去铁胺（DFO）试验是一种公认的估算体内铝含量的方法。然而，高剂量（30或40mg/kg）DFO试验经常报告有毒副作用。为了研究低剂量（500mg）DFO试验是否也有用且无副作用，我们在22例定期血液透析患者中将其与高剂量DFO试验进行了比较。在透析的前两小时，将100ml 0.9%氯化钠中的500mg DFO静脉给药。在透析前和48小时后测定血清中的铝浓度。在14例患者中，低剂量DFO试验被认为是阳性。在这14例患者中的11例中，高剂量（30mg/kg）DFO试验也为阳性。结果分析显示，同一患者的两种DFO试验结果之间存在显著相关性（p<0.05）。与高剂量DFO试验相比，低剂量试验的敏感性为79%，特异性为63%。与高剂量DFO试验相比，低剂量试验可能是一种可靠且安全的估算定期血液透析患者体内铝含量的方法。
